Peter A. McCullough, MD, MPH™ – Telegram
Peter A. McCullough, MD, MPH
27K subscribers
747 photos
611 videos
14 files
4.99K links
Physician-scientist, author, commentator, Chief Scientific Officer, The Wellness Company, President, McCullough Foundation, www.petermcculloughmd.com
Download Telegram
Please register for and attend this seminar by C19 hero Dr. Brian Tyson:

COVID 19 ECHO - Update on Steroid Use to Treat Symptoms of COVID-19
From: 9:00 PM, Tuesday, September 28, 2021
To: 10:00 PM, Tuesday, September 28, 2021
https://rcm.imrpress.com/EN/10.31083/j.rcm2203116 Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
MVC Cheers For Choice: Host April Moss, Dr. McCullough Keynote Speaker, Expert Panel: Comprehensive Review of COVID-19 Early Treatment and Vaccine Safety and Efficacy: https://www.youtube.com/watch?v=K-IgAxwSfzU
https://youtu.be/IJUY57bvnB8 Dr. Lindsey Berkson with Dr. Peter A. McCullough, MD, MPH of America Out Loud the McCullough Report
Colleagues

Please see this wonderfully written highly graphical piece from C19 Jack Lyons-Weiler, PhD, crediting many leaders the early treatment response for COVID-19. Please share wildly and feel free to use graphics.

https://popularrationalism.substack.com/p/who-are-the-words-leading-authorities
09/29/21

COVID › VIEWS

Safety Signals for COVID Vaccines Are Loud and Clear. Why Is Nobody Listening?
The public deserves a complete and transparent accounting of the Centers for Disease Control and Prevention’s safety monitoring, including the results of all interim reports and analyses, whether through an Freedom of Information Act request, Congressional order or some other means. https://childrenshealthdefense.org/defender/safety-signals-covid-vaccines-full-transparency-cdc-fda/
The push for prophylaxis and treatment of SARS-CoV-2 oropharyngeal infection starts in the nose and mouth. A randomized trial by Choudhury et al. from Bangladesh has been overlooked by US public agencies but not the early treatment organizations around the world. In this prospective randomized controlled trial, n=606 high-risk subjects with incipient COVID-19 were randomized to 1% povidone-iodine (betadine) solution as a rinse was used for a target of every 4 hours versus lukewarm water for four weeks.

Join us for the next COVID Q & A with Dr. Peter McCullough, on Sept 29, Wednesday, at 6 PM ET, and an encore at 10 PM ET on America Out Loud Talk Radio. Listen on iHeart Radio, our world-class media player, or our free apps on Apple, Android, or Alexa.

By day 7, the rates of positive nasal PCR for SARS-CoV-2 were 2.64% versus 70.3%, p<0.0001. The hospitalization rates and oxygen support and death rates were 3.3% vs. 20.8% and 0.66% vs. 5.61% (84% and 88% reductions, respectively) for the povidone-iodine vs. lukewarm water groups, p<0.0001. We know to apply these concepts to pre-exposure prophylaxis twice a day and postexposure four times a day. During active early treatment, it is reasonable to aim for every four hours with the goal of reducing viral load and reinoculation.

If there is iodine sensitivity or intolerance, then dilute hydrogen peroxide, dilute sodium hypochlorite, followed by Listerine or Scope mouthwash can be used in the mouth only with attention to not swallowing. For the nose, saline rinses, nasal ozone, and colloidal silver hydrosol can be used, but the randomized trial support is not present.

We have a wonderful show with guests Dr. Richard Urso from Houston, TX, who gives us his insights on the crisis. Finally, an early innovator and COVID-19 specialist, Ivette Lozano, from Dallas, TX, provides us with an update on obesity, diabetes, hyperglycemia, and weight loss during COVID-19 illness.

So let’s get real, let’s get loud, on America Out Loud Talk Radio, this is The McCullough Report! https://www.americaoutloud.com/keeping-clean-where-it-counts/